Data updated: Mar 10, 2026
CONRAY 43
IOTHALAMATE MEGLUMINE
Approved 1962-08-16
5
Indications
--
Phase 3 Trials
1
Priority Reviews
63
Years on Market
Details
- Status
- Discontinued
- First Approved
- 1962-08-16
- Routes
- INJECTION
- Dosage Forms
- INJECTABLE
CONRAY 43 Approval History
Loading approval history...
What CONRAY 43 Treats
5 FDA approvalsOriginally approved for its first indication in 1962 . Covers 5 distinct patient populations.
- Other (5)
Other
(5 approvals)- • Approved indication (Aug 1962) Priority
- • Approved indication (Oct 1978)
- • Approved indication (Oct 1982)
- • Approved indication (Jan 1983)
- • Approved indication (Sep 1985)
🔬
Pro Active Pipeline
Ongoing clinical trials by development phase
Loading...
⭐
Pro Key Completed Trials
Completed studies with published results, ranked by significance
Loading...
📊
Trial Timeline
Full development history with FDA approval milestones
Loading...
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
CONRAY 43 FDA Label Details
ProWant competitive intelligence?
See who's developing similar drugs and track their progress
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.